

# BW 245C

Catalog No: **tcsc6941**



## Available Sizes

**Size:** 1mg



## Specifications

**CAS No:**

72814-32-5

**Formula:**

$C_{19}H_{32}N_2O_5$

**Pathway:**

GPCR/G Protein

**Target:**

Prostaglandin Receptor

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

368.47


## Product Description

BW 245C is a **prostanoid DP-receptor (DP1)** agonist, used to treat stroke.

**In Vitro:** BW245C (0.01-1  $\mu$ M) suppresses TGF- $\beta$ -induced collagen secretion in a dose-dependent manner in Th2 cells. BW245C (0.01-1  $\mu$ M) also increases intracellular cAMP in lung fibroblasts<sup>[3]</sup>. BW245C (0.1-3  $\mu$ mol/L) dose-dependently increases transendothelial electrical resistance and decreases the FITC-dextran permeability of human umbilical vein endothelial cells. BW245C (0.3  $\mu$ mol/L) increases the intracellular cAMP level and subsequent protein kinase A (PKA) activity<sup>[4]</sup>.

**In Vivo:** BW245C (0.02, 0.2, and 2.0 mg/kg) in WT mice results in a significant increase in CBF, but this effect of this treatment is

absent in DP1<sup>-/-</sup> mice. BW245C attenuates functional deficits after stroke. BW245C significantly reverses these conditions that neurologic deficit is significantly augmented, whereas locomotor activity is significantly reduced after stroke in WT mice. BW245C (0.2 mg/kg) injection 1 h after stroke results in a significant decrease in brain infarction in WT mice, whereas the effect of this treatment is not observed in DP1<sup>-/-</sup> mice. BW245C improves CBF during and after stroke. BW245C results in significantly prolonged bleeding compared with the vehicle-treated group<sup>[1]</sup>. BW 245C (100 nM) does not significantly increase MBP-positive eosinophils in esophageal epithelium in OVA-sensitized guinea pigs<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!